{"id":49516,"date":"2026-08-18T05:57:21","date_gmt":"2026-08-18T05:57:21","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/coloplast-a-s-interim-financial-report-9m-2025-26\/"},"modified":"2026-08-18T05:57:21","modified_gmt":"2026-08-18T05:57:21","slug":"coloplast-a-s-interim-financial-report-9m-2025-26","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/coloplast-a-s-interim-financial-report-9m-2025-26\/","title":{"rendered":"Coloplast A\/S – Interim Financial Report, 9M 2025\/26"},"content":{"rendered":"

Interim financial results, 9M 2025\/26<\/strong>
1 October 2025 – 30 June 2026<\/p>\n

Coloplast delivered Q3 organic growth of 6% and 5% EBIT growth1<\/sup> in constant currencies. Strong quarter in <\/b>both Chronic Care ex. China and Interventional Urology; continued reimbursement-related challenges in <\/b>Biologics. Reported revenue in DKK also grew 6%, as currencies had a net neutral impact. Return on invested <\/b>capital after tax before special items was 15%. <\/b>
\u2022 Organic growth rates by business area: Ostomy Care 5%, Continence Care 8%, Voice & Respiratory Care 6%, Wound & Tissue Repair 3%, and Interventional Urology 7%.
\u2022 Strong quarter in Ostomy Care ex. China, with strong double-digit growth in the US and solid performance in Europe and Emerging markets ex. China.
\u2022 Strong quarter in Continence Care, with double-digit growth in the US and solid growth in Europe, driven by Luja.
\u2022 Solid quarter in Voice & Respiratory Care, with strong growth in Laryngectomy and softer quarter in Tracheostomy.
\u2022 Challenging quarter in Biologics with 6% sales decline and -5% EBIT margin before PPA amortisation, due to the reimbursement change.
\u2022 Advanced Wound Dressings grew 4%: good momentum in the US and positive impact from phasing in Germany and the Middle East, partly offset by the China product return.
\u2022 Continued strong momentum in Interventional Urology, driven by the US Men\u2019s Health business.
\u2022 EBIT1,2 <\/sup>was DKK 1,929 million. EBIT1,2 <\/sup>in constant currencies increased 5% compared to last year, while reported EBIT1,2 <\/sup>increased 1% from last year. The EBIT margin1,2 <\/sup>was 26%, against 28% last year, and includes around 110 basis points negative impact from currencies and around 60 basis points negative impact from Kerecis.<\/p>\n

9M 2025\/26 organic growth of 6% and 5% EBIT growth1<\/sup> in constant currencies. Reported revenue in DKK <\/b>grew 3%, reflecting 3%-points negative impact from currencies.<\/b>
\u2022 Organic growth rates by business area: Ostomy Care 5%, Continence Care 7%, Voice & Respiratory Care 7%, Wound & Tissue Repair 2%, and Interventional Urology 8%.
\u2022 EBIT1,2 <\/sup>was DKK 5,599 million. EBIT1,2 <\/sup>in constant currencies increased 5% compared to last year, while reported EBIT1,2 <\/sup>decreased 2% from last year. The EBIT margin1,2<\/sup> was 26%, against 27% last year, reflecting around 90 basis points negative impact from currencies and around 50 basis points negative impact from Kerecis.
\u2022 Net profit before special items was DKK 4,289 million, or a DKK 510 million increase from last year (adjusted for the non-recurring tax impact last year), positively impacted by lower net financial items due to gains on exchange rate adjustments, as expected. Adjusted diluted EPS before special items increased by 14%.
\u2022 The free cash flow-to-sales ratio was 20% vs. 16% last year3<\/sup>, reflecting favourable development in working capital and lower net financial items, partly offset by higher capital expenditures.
\u2022 Return on invested capital after tax before special items was 15%, on par with last year adjusted4<\/sup>.<\/p>\n

Unchanged FY 2025\/26 guidance: Organic revenue growth expected at 5-6%, EBIT growth in constant <\/b>currencies at around 5%5<\/sup>. Return on invested capital after tax before special items expected around 15%.<\/b>
\u2022 For organic revenue growth we expect continued good momentum in Chronic Care ex. China and high single-digit growth in Interventional Urology.
\u2022 Kerecis is expected to deliver around 0% organic growth and around 0% EBIT margin.
\u2022 Reported revenue growth in DKK is expected at around 3%, with 2-3%-points negative impact from currencies.
\u2022 Capex-to-sales ratio expected around 5%. The effective tax rate is expected around 22%.
\u2022 Special items is expected around DKK 3.1 billion, reflecting the DKK 3 billion Kerecis impairment loss.<\/p>\n

\u201dWe deliver a strong Q3 result with 6% organic growth and 5% EBIT growth, which means that we continue to help more and more people with intimate healthcare needs live better lives. My first 100 days have reinforced my conviction that Coloplast is a fundamentally strong company, operating in attractive markets, where we hold leadership positions and see significant growth opportunities. What stands out to me is the strength of our Chronic Care business, the significant untapped potential in the US, and the quality of our people. Today, I am sharing the priorities that I believe will be most important to driving long-term value creation\u201d says Gavin Wood, President & CEO.<\/p>\n

1. Before special items of DKK -18 million in Q3 2025\/26 and DKK -3,078 million in 9M 2025\/26. 2. Before special items of DKK -83 million in Q3 2024\/25 and DKK -241 million in 9M 2024\/25. 3. Excluding impact from the Uromedica acquisition this year and the Skin Care divestment last year. 4. Last year adjusted for the impact from the Kerecis IP transfer. 5. Before special items expenses of around DKK 3.1 billion in FY 2025\/26.<\/p>\n

<\/p>\n

Conference call<\/b><\/p>\n

Coloplast will host a conference call on Tuesday, 18 August 2026 at 11.00 am CEST. The call is expected to last about one hour.\u00a0
To actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here<\/a>
Access the conference call webcast directly here: Coloplast \u2013 9M 2025\/26 Earnings release conference call<\/a>\u00a0<\/p>\n

\u00a0<\/p>\n

For further information, please contact
<\/strong>\u00a0
Investors and analysts<\/em><\/strong>
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. +45 4911 1111<\/p>\n

Kristine Husted Munk
Sr. Director, Investor Relations
Tel. +45 4911 1800 \/ +45 4911 3266
Email:\u00a0dkkhu@coloplast.com<\/a><\/p>\n

Simone Dyrby Helvind
Sr. Manager, Investor Relations
Tel. +45 4911 1800 \/ +45 4911 2981
Email:\u00a0dksdk@coloplast.com<\/a><\/p>\n

Press and media<\/em><\/strong>
Peter M\u00f8nster
Head of Media Relations & Corporate Content
Tel. +45 4911 2623
Email:\u00a0dkpete@coloplast.com<\/a><\/p>\n

Address<\/em><\/strong>
Coloplast A\/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917<\/p>\n

Website<\/em><\/strong>
www.coloplast.com<\/a><\/p>\n

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.<\/p>\n

\u00a0<\/p>\n

The Coloplast story begins back in 1954. Elise S\u00f8rensen is a nurse. Her sister Thora has just had an ostomy operation and is afraid to go out in public, fearing that her stoma might leak. Listening to her sister\u2019s problems, Elise conceives the idea of the world\u2019s first adhesive ostomy bag.
Based on Elise\u2019s idea, Aage Louis-Hansen, a civil engineer and plastics manufacturer, and his wife Johanne Louis Hansen, a trained nurse, created the ostomy bag.\u00a0A bag that does not leak, giving Thora \u2013 and thousands of people like her \u2013 the chance to live the life they want.\u00a0
A\u00a0simple solution that makes a difference.\u00a0
Today, the Coloplast Group develops products and services that help millions of people live more independent lives through solutions tailored to their needs. Globally, our business areas include Ostomy Care, Continence Care, Voice & Respiratory Care, Wound & Tissue Repair, and Interventional Urology.<\/p>\n

\u00a0\u00a0<\/p>\n\n\n
The Coloplast logo is a registered trademark of Coloplast A\/S. \u00a9 2026-08
All rights reserved Coloplast A\/S, 3050 Humlebaek, Denmark<\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n<\/p>\n